Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

about

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

Item

http://www.wikidata.org/entity/Q47115045

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@en

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@nl

type

Item

label

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@en

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@nl

prefLabel

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@en

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@nl

P1476

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

@en

P2093

B N Lokesh

http://www.w3.org/2001/XMLSchema#string

Nishant Garodia

http://www.w3.org/2001/XMLSchema#string

Ravi Santani

http://www.w3.org/2001/XMLSchema#string

Vishal Gupta

http://www.w3.org/2001/XMLSchema#string

William Canovatchel

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives

Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents

Diabetic kidney disease: from physiology to therapeutics

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Adverse effects and safety of SGLT-2 inhibitors

Metformin and metabolic diseases: a focus on hepatic aspects

The Economic Costs of Type 2 Diabetes: A Global Systematic Review

P304

909-918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJEM.IJEM_85_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285458

http://www.w3.org/2001/XMLSchema#string

P932

5729683

http://www.w3.org/2001/XMLSchema#string